TACE联合免疫和靶向药物方案在HCC患者中的应用效果分析  

Analysis of the Application Effect of TACE Combined with Immunotherapy and Targeted Drug Regimen in Patients with HCC

作　　者：罗德荣 Luo Derong(Affiliated Cancer Hospital of Guizhou Medical University,Guiyang,Guizhou 550001)

机构地区：[1]贵州医科大学附属肿瘤医院,贵州贵阳550001

出　　处：《科技与健康》2025年第3期77-80,共4页Technology and Health

摘　　要：评估经导管动脉栓塞化疗(transcatheter arterial chemoembolization,TACE)联合免疫和靶向药物方案在晚期肝细胞癌(hepatocellular carcinoma,HCC)患者中的疗效和安全性。纳入2022年1月—2024年8月在贵州医科大学附属肿瘤医院接受治疗的80例晚期HCC患者为研究对象,采用随机数字表法将其分为观察组和对照组,每组各40例。观察组接受TACE和信迪利单抗联合贝伐珠单抗治疗,对照组接受TACE和甲磺酸仑伐替尼联合替雷利珠单抗治疗,评估两组患者的治疗效果。结果显示,观察组疗效优于对照组(P<0.05)。治疗前,两组患者的血清肿瘤相关因子水平对比,无统计学差异(P>0.05);治疗后,观察组AFP、PIVKA-Ⅱ、HSPs及GGT水平均低于对照组(P<0.05)。两组患者的不良反应发生率对比,无统计学差异(P>0.05)。研究发现,TACE和信迪利单抗联合贝伐珠单抗方案在提高晚期HCC患者病情控制率方面的效果优于甲磺酸仑伐替尼联合替雷利珠单抗。To evaluate the effcacy and safety of transcatheter arterial chemoembolization(TACE)combined with immunotherapy and targeted drug regimen in patients with advanced hepatocellular carcinoma(HCC).A total of 80 patients with advanced HCC who received treatment in the Affiliated Cancer Hospital of Guizhou Medical University from January 2022 to August 2024 were included as the research subjects.They were divided into an observation group and a control group by the random number table method,with 40 cases in each group.The observation group received TACE combined with Sintilimab and Bevacizumab,while the control group received TACE combined with Lenvatinib Mesylate and Toripalimab,and the treatment effects of the two groups were evaluated.The results showed that the curative effect of the observation group was better than that of the control group(P<0.05).Before treatment,there was no significant difference in the levels of serum tumor-related factors between the two groups(P>0.05).After treatment,the levels of AFP,PIVKA-Ⅱ,HSPs and GGT in the observation group were all lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).It is found that the regimen of TACE combined with Sintilimab and Bevacizumab is more effective than the combination of Lenvatinib Mesylate and Toripalimab in improving the disease control rate of patients with advanced HCC.

关 键 词：晚期肝细胞癌 信迪利单抗 贝伐珠单抗 甲磺酸仑伐替尼 替雷利珠单抗 

分 类 号：R735.7[医药卫生—肿瘤]